...
首页> 外文期刊>Cellular Physiology and Biochemistry >Astragaloside IV Induced miR-134 Expression Reduces EMT and Increases Chemotherapeutic Sensitivity by Suppressing CREB1 Signaling in Colorectal Cancer Cell Line SW-480
【24h】

Astragaloside IV Induced miR-134 Expression Reduces EMT and Increases Chemotherapeutic Sensitivity by Suppressing CREB1 Signaling in Colorectal Cancer Cell Line SW-480

机译:黄芪甲苷IV诱导的miR-134表达通过抑制结直肠癌细胞系SW-480中的CREB1信号传导而降低EMT并增加化学敏感性。

获取原文

摘要

>Background: Colorectal cancer (CRC) is one of the leading causes of cancer-related deaths worldwide. Although chemotherapy is the primary means in colorectal cancer treatment, it is burdenerd by adverse drug effects. Drug-resistance is one of the most important challenges for chemotherapy and epithelial-mesenchymal transition (EMT) plays critical role in the development of drug resistance. Aims: The aim of this study was to investigate the mechanisms underlying the effect of astragaloside IV (AS-IV) on miR-134 expression, EMT and chemotherapeutic sensitivity in CRC. Methods: Cell proliferation, transfection assay, western blot, real-time PCR, cell migration and invasion assay and luciferase reporter assay were used to detect the effects of AS-IV on CRC. Results: AS-IV significantly inhibited CRC cell migration and invasion by inducing miR-134 expression. Moreover, AS-IV and miR-134 increased the sensitivity of CRC tumors to oxaliplatin (OXA) chemotherapy. cAMP responsive element-binding protein 1 (CREB1), which was required for CRC cells migration, invasion and drug sensitivity, was significantly down-regulated by AS-IV. Conclusions: Our results indicated that AS-IV inhibited CRC EMT by inducing miR-134 expression which significantly down-regulated the CREB1 signaling pathway, and therefore increased the sensitivity to chemotherapy. Our findings provided new insight into the mechanisms of chemotherapy-resistant CRC, and may open new therapeutic options in the treatment of this devastating disease.
机译:> 背景: 大肠癌(CRC)是全球范围内与癌症相关的死亡的主要原因之一。尽管化学疗法是大肠癌治疗的主要手段,但药物不良作用使化学疗法负担重。耐药性是化学疗法最重要的挑战之一,上皮-间质转化(EMT)在耐药性的发展中起着至关重要的作用。 目的: 这项研究的目的是研究黄芪甲苷IV(AS-IV)对CRC中miR-134表达,EMT和化学敏感性的影响的潜在机制。 方法: 使用细胞增殖,转染测定,蛋白质印迹,实时PCR,细胞迁移和侵袭测定以及荧光素酶报告基因测定来检测AS-IV对CRC。 结果: AS-IV通过诱导miR-134表达来显着抑制CRC细胞的迁移和侵袭。此外,AS-IV和miR-134增加了CRC肿瘤对奥沙利铂(OXA)化疗的敏感性。 AS-IV显着下调了CRC细胞迁移,侵袭和药物敏感性所需的cAMP响应元件结合蛋白1(CREB1)。 结论: 我们的结果表明,AS-IV通过诱导miR-134表达来抑制CRC EMT,从而显着下调CREB1信号通路,从而增加了对化疗的敏感性。我们的发现为对化疗耐药的CRC的机制提供了新的见解,并可能为治疗这种毁灭性疾病开辟新的治疗选择。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号